1. Scrip
  2. >>Therapy Areas

Swiss R&D Innovation: A Tale Of Two Firms Developing Cell Therapies For Wounds

Dermatology Takes The Spotlight

 
• By Ayisha Sharma

While perhaps best known for historical achievements in immuno-oncology and CNS disorders, the Swiss biotech sector is slowly cultivating a new area of expertise in dermatology. Scrip spoke with two firms applying cell therapy technologies to the challenging area of chronic and acute wounds.  

Swiss Biotech Focus
• Source: Shutterstock

The Swiss biotech sector often reflects global trends, with many firms active in developing cancer therapeutics. The nation has a particularly strong track record in antibody R&D and was ranked as a key growth center for oncology by McKinsey & Company in 2021, defined as countries with the largest growth in company numbers in the relevant therapeutic area since 2015.

The country is also known for its expertise in CNS disorders, where it was ranked by McKinsey as a leading center – part of the top-three European companies in terms of number of the companies in the area

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

More from Therapy Areas

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Merck’s Welireg Adrenal Tumor Rollout Targets Specialized Centers

 
• By Alaric DeArment

The drugmaker won US FDA approval for the HIF-2α inhibitor in pheochromocytoma and paraganglioma, a rare cancer of the adrenal glands, in adolescents and adults.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.